Although recombinant human growth hormone significantly improved the patient's growth rate (from -3.35 SD to -1.28 SD), these variants may serve as a potential molecular basis for Nijmegen Breakage Syndrome-like disease and could also increase the risk of tumor formation. This evidence concerns the gene GH1 and neoplasm.